Compare LITE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITE | IKT |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 240.1M |
| IPO Year | 2015 | 2020 |
| Metric | LITE | IKT |
|---|---|---|
| Price | $870.81 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $645.43 | $5.00 |
| AVG Volume (30 Days) | ★ 5.1M | 675.8K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.56 | 57.76 |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $1,247,700,000.00 | N/A |
| Revenue This Year | $79.88 | N/A |
| Revenue Next Year | $66.61 | N/A |
| P/E Ratio | $365.03 | ★ N/A |
| Revenue Growth | ★ 24.57 | N/A |
| 52 Week Low | $80.39 | $1.33 |
| 52 Week High | $1,085.68 | $2.26 |
| Indicator | LITE | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 38.77 |
| Support Level | $820.17 | $1.51 |
| Resistance Level | $942.75 | $1.74 |
| Average True Range (ATR) | 85.83 | 0.09 |
| MACD | -6.69 | -0.01 |
| Stochastic Oscillator | 24.00 | 36.54 |
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.